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Key Point Summary 
 SCFAs are bacterial metabolites produced during colonic fermentation of undigested 
carbohydrates, such as dietary fibre and prebiotics, and could mediate the interaction 
between diet, the microbiota and the host. 
 We quantified the fraction of colonic administered SCFA that could be recovered in the 
systemic circulation, the fraction that was excreted via breath and urine and the fraction 
that was used as a precursor for glucose, cholesterol and fatty acids. 
 This information is essential to understand the molecular mechanisms by which SCFA 
beneficially affect physiological functions such as glucose and lipid metabolism and 
immune function. 
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Abstract 
The short-chain fatty acids (SCFAs), acetate, propionate and butyrate are bacterial metabolites 
that mediate the interaction between diet, the microbiota and the host. In this study, the systemic 
availability of SCFAs and their incorporation into biologically relevant molecules was 
quantified. Known amounts of 13C-labelled acetate, propionate and butyrate were introduced 
in the colon of 12 healthy subjects using colon delivery capsules and plasma levels of 
13C-SCFAs and of 13C-glucose, 13C-cholesterol and 13C-fatty acids were measured. The 
butyrate producing capacity of the intestinal microbiota was quantified as well. Based on 
plasma exposure, Systemic availability of colonic-administered acetate, propionate and 
butyrate was 36%, 9% and 2%, respectively. Conversion of acetate into butyrate (24%) was 
the most prevalent interconversion by the colonic microbiota and was not related to the 
butyrate-producing capacity in the faecal samples. Less than 1% of administered acetate was 
incorporated into cholesterol and <15% in fatty acids. On average, 6% of colonic propionate 
was incorporated into glucose. The SCFAs were mainly excreted via the lungs after oxidation 
to 13CO2 whereas less than 0.05% of the SCFAs were excreted into urine. These results will 
allow future evaluation and quantification of SCFAs production from 13C-labelled fibres in the 
human colon by measuring 13C-labelled SCFA concentrations in blood. 
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Abbreviation list 
AUC, area under the curve; CDC: colonic delivery capsule; Cl, clearance; Css ,steady state 
concentration; cumPDR, cumulative percentage of administered dose; D, administered dose; 
FFAR, free fatty acid receptor; GC-C-IRMS, gas chromatography combustion isotope ratio 
mass spectrometry; GC-MS, gas chromatography mass spectrometry; GPR, G-protein coupled 
receptor; I, infusion rate; MCT, monocarboxylate transporter; OCTT, orocecal transit time; 
RT-PCR, real time polymerase chain reaction; SA, systemic availability; SCFA, Short-chain 
fatty Acid; TCA, tricarboxylic acid; T20% , time of release of the CDC 
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Body of paper 
Introduction 
Short chain fatty acids, mainly comprising acetate, propionate and butyrate are produced in the 
large intestine by microbial degradation of undigested carbohydrates and to a lesser extent 
proteins. They are increasingly recognised as signalling molecules that mediate the interaction 
between the diet, the gut microbiota and the host. Locally in the gut, SCFA are crucial for 
intestinal health because they serve as the major energy substrates for the colonocytes and 
because of their anti-inflammatory and anti-carcinogenic properties (Hamer et al., 2008). In 
addition, they affect gut and host metabolism by activating the G-protein coupled cell surface 
receptors GPR-41 and GPR-43 (Brown et al., 2003), later renamed as free fatty acid receptors 
(FFAR)-3 and FFAR-2, that are involved in the regulation of glucose and lipid metabolism 
(den Besten et al., 2013b). Activation of those receptors on the enteroendocrine L-cells in the 
colon results in the secretion of the gut-derived satiety hormones glucagon-like peptide 1 (GLP-
1) and peptide YY (PYY), providing a mechanism for the beneficial effect of SCFA on energy 
intake and satiety (Canfora et al., 2015). Finally, a fraction of the colonic produced SCFA 
reaches the systemic circulation and directly affects the function and metabolism of peripheral 
organs and tissues such as the liver, the pancreas, adipocytes, immune cells and skeletal muscle 
tissue. As a consequence, SCFA have been involved in maintaining glucose and lipid 
metabolism and may provide an important target to tackle disorders that are associated with 
disturbances of glucose and lipid metabolism such as obesity, metabolic syndrome or type 2 
diabetes. 
To further understand how SCFAs provide a mechanistic link between the diet, the microbiota 
and health benefits, it is absolutely necessary to quantify the extent to which fermentation-
derived SCFAs reach the systemic circulation. Quantitative information on the assimilation of 
SCFAs into biologically relevant molecules in humans may also contribute to unravelling the 
mechanism via which SCFAs elicit systemic effects. Currently, SCFAs are most often 
measured in faeces or in fasting blood samples. However, because of the rapid absorption of 
SCFAs by the colonocytes, only an estimated 5% of produced SCFAs is excreted in faeces 
(McNeil et al., 1978) rendering faecal measurements not representative for colonic SCFA 
production. In addition, the extensive metabolism in colonocytes and the liver results in low 
plasma levels of SCFAs. 
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In this work, stable isotope technology was applied to determine the systemic availability of 
each SCFA after colonic administration of 13C-labelled SCFAs. The systemic availability is 
the fraction of an administered dose of unchanged substrate that reaches the systemic 
circulation. In addition, the occurrence of interconversions was evaluated and the incorporation 
of the colonic-derived 13C-SCFAs into glucose, free fatty acids and cholesterol was quantified. 
Stable isotope technology is a very sensitive analytical technique that allows measuring 
selectively in plasma those SCFAs that originate from the colon. 
 
Materials & Methods 
Ethical Approval 
The study procedure was approved by the Ethics Committee of the Leuven University Hospital, 
Leuven, Belgium. Written, informed consent was obtained from all subjects and the study 
conformed to the Declaration of Helsinki. The study was registered at ClinicalTrials.gov 
(NCT01757379). 
Colonic Delivery of SCFAs 
Known amounts of the individual 13C-labelled SCFAs (13C-acetate, 13C-propionate or 
13C-butyrate) were delivered into the colon of healthy subjects using colon delivery capsules 
(CDCs). Hard gelatine capsules (size 0) were filled with either approximately 200 mg of 
13C-labelled sodium acetate ([1-13C]acetate), 170 mg of 13C-labelled sodium propionate 
([1-13C]propionate) or 495 mg of 13C-labelled sodium butyrate ([1-13C]butyrate) (Euriso-top, 
St Aubin, Cédex, France) together with 9.0% (w/w) citric acid (Sigma-Aldrich, Bornem, 
Belgium). The addition of citric acid was necessary to keep the pH of the capsule contents 
below pH 6.5 and to prevent in this way dissolution of the coating from the inside-out due to 
water intrusion into the capsules. Before and after filling, the capsules were weighed to 
determine their exact content. The capsules were coated manually with a pH-dependent film 
made up of Eudragit S100 (Evonik, Darmstadt, Germany) with diethyl phthalate (Omega 
Pharma, Nazareth, Belgium) (25% w/w with respect to polymer) as plasticizer. Eudragit S100 
only dissolves at a pH > 7.0 (Chourasia et al. 2003). The coating thickness was estimated from 
the increase in weight after coating and expressed in mg/cm² capsule surface. Coating thickness 
was varied between 13.5 mg/cm² and 23.3 mg/cm². 
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Similar capsules containing 5.2 mg (in acetate capsules) or 4.0 mg (in propionate and butyrate 
capsules) methylene blue were prepared to assess the pH resistance of the polymer coating. 
The release of methylene blue from the coated capsules was monitored during in vitro 
dissolution tests in sodium phosphate buffers (0.1 M) of pH 6.3, 6.8, 7.0 and 7.2 according to 
the USP XXV paddle method (150 rpm) at 37 °C. The concentration of the marker was 
quantified colorimetrically at 664 nm. All measurements were performed in duplicate. 
Study Design 
Twelve healthy subjects (7 F/ 5 M, aged 26 ± 6 years, BMI 22 ± 3 kg/m2) participated in a 
randomized cross-over study. Exclusion criteria were previous abdominal surgery (except from 
appendectomy), history of chronic gastro-intestinal conditions such as inflammatory bowel 
diseases, irritable bowel syndrome and celiac disease, or being on a low calorie or vegetarian 
diet. Female subjects were excluded if pregnant or lactating. All subjects were free of 
medication influencing the gut transit or intestinal microbiota for 14 days and of antibiotics for 
1 month. Intake of pre- and probiotics was prohibited during the study period. Subjects were 
also excluded if they had donated blood during the last three months, suffered from low blood 
haemoglobin levels or had participated in experiments involving ionizing radiation during the 
last year. Each subject performed three test days (one type of SCFA per test day) with one 
week in between. During the three days prior to a test day, the subjects consumed a low-fibre 
diet and avoided alcohol intake. On the evening prior to the test day, a non-fermentable 
standard meal (lasagne) was offered to avoid changes in colonic fermentation during the 
different test days. In the morning of the test, the subjects received two coated capsules 
containing either 13C-acetate, 13C-propionate or 13C-butyrate with a standard breakfast 
(pancake, 250 kcal) labelled with inulin-14C-carboxylic acid (74 kBq, American Radiolabelled 
Chemicals, St. Louis, MO, USA) as a marker for orocecal transit time (OCTT) (Verbeke et al., 
2005). During each test day, a primed continuous intravenous infusion of deuterated SCFAs 
was applied ([2H3]-acetate: 10 µmol.kg
-1 + 20 µmol.kg-1.h-1; [2H5]-propionate: 1 µmol.kg
-
1 + 2 µmol.kg-1.h-1; [2H7]-butyrate: 0.5 µmol.kg
-1 + 1 µmol.kg-1.h-1) to quantify the clearance 
of each SCFA. Before the breakfast and at regular time points during the day, breath, blood 
and urine samples were collected. Breath samples were collected every 20 min up to 10 h after 
breakfast. Blood samples were collected every hour during the first 4 h, every 20 min from 4 
to 9 h and every 40 min from 9 h to 12 h. A basal urine sample and 0-4 h, 4-8 h, 8-12 h and 
12-24 h urine fractions were collected in recipients containing neomycin to prevent bacterial 
growth. After 4 h and 8 h, the subjects received a standard non-fermentable meal (white bread 
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with ham or cheese). Finally, all subjects delivered a faecal sample that within 10 h after 
collection was frozen at -80 °C until analysis.  
Analytical Procedures 
Analysis of Breath Samples. Measurements of 13CO2, H2 and 
14CO2 in breath samples were 
performed as described previously (Verbeke et al., 2005). The results for 13CO2 were expressed 
as cumulative percentages of administered dose (cumPDR) (Braden et al., 2007). The time of 
release from the capsules (T20%) was defined as the time at which 20% of the cumPDR was 
recovered in breath. The cumPDR values after 12 h were corrected for 13CO2 that is produced 
via oxidation but is not excreted using a correction factor of 0.55 as suggested by Maurer et al. 
(Maurer et al., 2013). The OCTT was defined as the time at which a significant increase in 14C 
from background was seen in breath, i.e. 2.5 times the standard deviation of all previous points 
above the running average of all previous points (Verbeke et al., 2005). 
Analysis of Total SCFA Concentrations in Plasma and Urine Samples. Total SCFA 
concentrations in plasma were measured using gas chromatography (GC) after purification and 
concentration of the samples with hollow fibre supported liquid membrane extraction as 
described by Zhao et al. (Zhao et al., 2007). To measure total SCFA concentrations in urine, 
samples (3.0 mL) were spiked with 150 µL internal standard mix (83 mg.L-1 2-ethyl-butyric 
acid and 200 mg.L-1 3-methyl-valeric acid) and 500 µL of 1.0 M sodium hydroxide and 
concentrated to dryness. After addition of 200 µL 37.0% HCl to the residue, SCFAs were 
extracted in 1.0 mL diethyl ether. The ether extracts were were injected (0.5 µL) in pulsed 
splitless mode into the injector at 200 °C. Chromatographic analysis was carried out on a fused-
silica capillary column with Free Fatty Acid Phase (DB-FFAP 125–3237, J&W Scientific, 
Agilent Technologies, Santa Clara, California, USA) of 30 m × 0.53 mm i.d. coated with 
0.50 µm film thickness using an Agilent 6890N GC system equipped with a flame ionization 
detector (Agilent Technologies). Column temperature was started at 100 °C (3 min) and 
increased to 140 °C (5 min) at a rate of 4 °C/min followed by an increase to 235 °C (5 min) at 
a rate of 40 °C/min. Helium was used as carrier gas in a constant flow mode of 4.2 mL/min and 
the detector temperature was set at 240 °C. The flow rates of the detector gases hydrogen, air 
and nitrogen as makeup gas were 30, 300 and 20 mL/min, respectively. Data handling was 
carried out with a HP ChemStation Plus software (B.04.03, Agilent Technologies). 
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Analysis of 13C- and 2H-enrichments of SCFA in Plasma and Urine Samples. Plasma samples 
were deproteinised and extracted according to Morrison et al. (Morrison et al., 2004) whereas 
urine samples were only dried and extracted. The extracted samples for analysis of 
13C-enrichment of SCFAs were injected (4 µL) in splitless mode at 240 °C into a Delta-XP 
isotope ratio mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with 
a Trace gas chromatograph and a combustion interface type 3 (GC-C-IRMS). An 
AT-Aquawax-DA column (30 m x 0.53 mm i.d. and 1.00 µm film thickness; Grace, Lokeren, 
Belgium) was used. The initial oven temperature was 80 °C (3 min) and ramped to 140 °C at a 
rate of 4 °C/min followed by an increase to 240 °C (10 min) at a rate of 16 °C/min. Helium 
was used as carrier gas in a constant flow mode of 2.5 mL/min. After elution from the GC 
column, the compounds were oxidized into CO2 in the combustion reactor after which the 
enrichment was measured in the IRMS detector. To calculate the enrichment of the SCFAs 
from the measured 13CO2 enrichment, the number of labelled carbon atoms per molecule and 
the enrichment of the administered substrate (13C-SCFAs) were taken into account. Data were 
processed using Isodat NT (version 2.0, Finnigan™, Thermo Fisher Scientific).  
For the analysis of the 2H-enrichments of SCFAs, 1 µL of the extracted samples was injected 
at 240 °C in splitless mode into the injector of a gas chromatograph equipped with a quadrupole 
system (Trace GC Ultra and DSQ II, Thermo Electron Corporation, Waltham, MA, USA) with 
an AT-Aquawax DA column (30 m x 0.25 mm i.d. and 0.25 µm film thickness; Grace). The 
initial oven temperature was 40 °C (3 min) and ramped to 140 °C at a rate of 4 °C/min followed 
by an increase to 240 °C (6 min) at a rate of 16 °C/min. Helium was used as carrier gas in a 
constant flow mode of 1 mL/min. The transfer line was maintained at 240 °C. The mass 
spectrometer was operated in full scan monitoring mode (m/z 33-650) and the source 
temperature was set at 250 °C. XcaliburTM software (Thermo Fisher Scientific) was used for 
the automatisation of the GC-MS system and for data acquisition. 
Analysis of 13C-glucose. Total plasma glucose concentrations and 13C-glucose enrichments 
were measured using GC-C-IRMS after derivatization of glucose to its aldonitrile penta acetate 
derivative according to Schierbeek et al. (Schierbeek et al., 2009). The derivatized samples 
were injected (1 µL) in splitless mode into the GC-C-IRMS instrument equipped with an 
AT-5ms capillary column (30 m x 0.32 mm i.d. and 1.0 µm film thickness; Grace). The injector 
temperature was set at 250 °C and the initial oven temperature amounted to 95 °C (30 s) and 
was increased to 300 °C (15 min) at 20 °C/min. The helium carrier flowed at a constant rate of 
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1.5 mL/min. To calculate the enrichment of 13C-glucose from the measured enrichment of 
13CO2, it was assumed that one propionate molecule was incorporated per glucose molecule.  
Analysis of 13C-free fatty acids. The concentrations and 13C-enrichment in plasma of palmitic 
(C16:0), stearic (C18:0) and oleic (C18:1, n-9) acid were measured using GC-C-IRMS after 
prior conversion of the fatty acids into their corresponding methyl esters as described by Wang 
et al. (Wang et al., 2012). Samples were injected (1 µL) at 250 °C in a splitless mode into an 
AT-aquawax-DA column (30 m x 0.53 mm i.d. and 1.0 μm film thickness; Grace). The initial 
oven temperature was 50 °C (2 min) and ramped to 200 °C (10 min) at a rate of 10 °C/min 
followed by an increase to 220 °C (15 min) at a rate of 10 °C/min. Helium was used as carrier 
gas in a constant flow mode of 2.5 mL/min. To calculate the enrichment of 13C-fatty acids from 
the measured enrichment of 13CO2, we assumed that one acetate molecule was incorporated 
per fatty acid molecule. 
Analysis of 13C-cholesterol. Plasma samples for 13C-enrichment measurements of cholesterol 
were saponified and extracted in sequence with hexane and diethyl ether according to Paik et 
al. (Paik et al., 2008). The supernatant layer was silylated using 
N,O-bis(trimethylsilyl)trifluoroacetamide. The 13C-enrichment of cholesterol in plasma 
samples was measured using GC-C-IRMS analysis with an Rxi-5ms capillary column (30 m × 
0.25 mm i.d. and 0.5 µm film thickness; Interscience, Breda, The Netherlands). Samples were 
injected (1 µL) in splitless mode at 250 °C into the column. The initial oven temperature was 
240 °C (1 min) and was increased to 300 °C (15 min) at 20 °C/min. Helium gas was used as 
carrier gas and flowed at a constant rate of 2.5 mL/min. To calculate the enrichment of 
13C-cholesterol from the measured enrichment of 13CO2, it was assumed that one acetate or 
propionate molecule was incorporated per cholesterol molecule. Total cholesterol 
concentrations were determined using standard laboratory techniques.  
Analysis of Butyrate-producing Capacity in Faecal Samples. Real-time PCR was used to 
quantify Clostridium cluster IV, Clostridium cluster XIV, butyryl-CoA:acetate-CoA 
transferase and butyrate kinase genes in faecal samples as described previously (Boets et al., 
2015). 
Calculations 
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Systemic availabilities of colonic acetate, propionate and butyrate. The systemic availability 
of each SCFA was determined by measuring 13C-acetate, 13C-propionate and 13C-butyrate 
plasma concentrations up to 12 h after colonic delivery of 13C-acetate, 13C-propionate and 
13C-butyrate, respectively, on three separate test days. At each time point, total 
(labelled + unlabelled) SCFA concentrations and 13C-SCFA enrichments were measured. The 
plasma concentration of 13C-SCFAs consists of the concentration of 13C-SCFAs naturally 
present in the plasma and the concentration originating from the colon. The concentration of 
13C-SCFAs originating from the colon at each time point (ncolon) was calculated according to 
equation 1 and allowed constructing 13C-SCFA concentration versus time graphs: 
 𝑛𝑐𝑜𝑙𝑜𝑛 =  𝑛𝑡𝑜𝑡 𝑥 
𝐴𝑃𝑡𝑜𝑡− 𝐴𝑃𝑝𝑙𝑎𝑠𝑚𝑎 𝑡0
𝐴𝑃𝑐𝑜𝑙𝑜𝑛−𝐴𝑃𝑝𝑙𝑎𝑠𝑚𝑎 𝑡0
 (equation 1) 
with ntot: total concentration of SCFAs (labelled + unlabelled), APtot: 
13C-enrichment of the 
SCFAs measured in plasma at time point t, AP plasma t0: 
13C-enrichment of the SCFAs measured 
in plasma at time 0, and APcolon: 
13C-enrichment of the administered substrate. 
To allow calculating the clearance of the SCFAs, a primed constant infusion with 2H-SCFAs 
was applied during each test day. The 2H-enrichments of the SCFAs were multiplied with the 
SCFA plasma concentrations to calculate the 2H-SCFA concentrations. Subsequently, the 
clearance (Cl, L.h-1) was calculated from the 2H-SCFA infusion rate (I2H-SCFA, µmol.h
-1) and 
the steady state 2H-SCFA plasma concentration (Css, µmol.L
-1) according to equation 2: 
 𝐶𝑙 =  
𝐼
𝐻−𝑆𝐶𝐹𝐴2
𝐶𝑆𝑆
 (equation 2) 
13C-SCFA concentration versus time graphs were used to calculate the exposure to 13C-SCFAs 
in plasma using the trapezoidal rule. Finally, knowing the administered amount of each 
13C-SCFA, the systemic availability of 13C-acetate, 13C-propionate and 13C-butyrate was 
calculated according to equation 3: 
 𝑆𝐴𝑆𝐶𝐹𝐴 =
𝐴𝑈𝐶 𝑥 𝐶𝑙𝑆𝐶𝐹𝐴
𝐷𝑐𝑎𝑝𝑠𝑢𝑙𝑒
 × 100 (equation 3) 
with SA: systemic availability (%), AUC: area under the curve of the 13C-SCFA concentration 
versus time graph (µmol.h.L-1), Cl: clearance of the respective SCFA (L.h-1), and Dcapsule: 
administered dose of the respective SCFA (µmol). 
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Assimilation of SCFAs into biologically relevant molecules. The fraction of colonic-derived 
propionate used for glucose production was quantified from the cumulative amount of 
13C-glucose appearing in the plasma after colonic administration of 13C-propionate according 
to equation 4. 
  𝐹13𝐶−𝑙𝑎𝑏𝑒𝑙 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑎𝑠 𝑔𝑙𝑢𝑐𝑜𝑠𝑒  =
𝐴𝑈𝐶 𝑥 𝐶𝑙𝑔𝑙𝑢𝑐𝑜𝑠𝑒
𝐷13𝐶−𝑝𝑟𝑜𝑝𝑖𝑜𝑛𝑎𝑡𝑒
 × 100 (equation 4) 
with F13C-label recovered as glucose: the fraction of administered 
13C recovered in glucose (%), AUC: 
the area under the curve of the 13C-glucose versus time graph (µmol.h.L-1), Clglucose: the 
clearance (L.h-1) of glucose that was calculated for each individual according to Jani et al. (Jani 
et al., 2008) and amounted to 8.9 ± 1.2 L.h-1, and D13C-propionate: the dose of colonic administered 
13C-propionate (µmol). 
Similarly, the fraction of 13C-acetate incorporated into the most abundant fatty acids (palmitic, 
stearic and oleic acid) was calculated according to equation 4 using the respective AUCs of the 
13C-fatty acids versus time graphs, the clearance of palmitic, stearic and oleic acid, respectively, 
and the administered dose of 13C-acetate. The clearance of the fatty acids was obtained from 
literature and amounted to 48, 30 and 45 L.h-1 for palmitic, stearic and oleic acid, respectively. 
Finally, the extent to which intestinal acetate and propionate were used for de novo synthesis 
of cholesterol was determined. The fractional incorporation of 13C-acetate and 13C-propionate 
into cholesterol was calculated according to equation 4 using the AUC of the 13C-cholesterol 
versus time graph, the clearance of cholesterol and the administered dose of 13C-acetate and 
13C-propionate, respectively. The clearance of cholesterol was calculated for each individual 
based on his/her body weight and cholesterol levels as described by Turner et al. (Turner et al., 
2012) and amounted to 0.15 ± 0.04 L.h-1. 
Statistical analysis 
Statistical analyses were performed using SPSS, version 22.0 (IBM Corp, New York, USA). 
All results are presented as means ± standard deviations (SDs). Assumptions of normality were 
checked with a Shapiro-Wilk test. The OCTT and time of 13CO2 in breath samples were 
compared with a paired samples T-test. Bivariate correlations were performed with Spearman’s 
rho. Significance was accepted at the 5% level.  
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Results 
Delivery of SCFAs into the colon of healthy subjects 
In vitro dissolution tests indicated an appropriate release profile of the marker methylene blue 
from the CDCs (release after 45 min at pH = 7.0) with a coating thickness of 18.8 mg/cm² 
capsule surface (Figure 1 A).  
To evaluate the in vivo performance of the capsules, the time at which 13CO2, resulting from 
oxidation of released 13C-SCFAs, appeared in breath was compared with the OCTT which was 
estimated from an increase of 14CO2 in breath (Verbeke et al., 2005). A simultaneous increase 
in breath of 13CO2 and 
14CO2 indicates a correct release of the CDCs content in the proximal 
colon (Figure 1 B). No significant differences were observed between the 13CO2 excretion time 
(383 ± 105 min) and the OCTT (399 ± 84 min) in any of the test days (p = 0.202) (Figure 1 C).  
Systemic availabilities of colonic acetate, propionate and butyrate 
13C-SCFA concentration versus time graphs were constructed for the three test days of each 
subject and a representative example is shown Figure 2 A. By calculating the area under these 
13C-SCFA concentrations versus time graphs an exposure of 1.92 ± 1.13, 0.48 ± 0.26 and 
0.21 ± 0.20 µmol.h.L-1 was obtained for 13C-acetate, 13C-propionate and 13C-butyrate, 
respectively. Total body clearance of acetate, propionate and butyrate amounted to 938 ± 287, 
647 ± 176 and 1237 ± 592 L.h-1, respectively. On average, the fraction of colonic-derived 
acetate, propionate and butyrate appearing in plasma amounted to 36 ± 21%, 9.2 ± 5.9% and 
2.4 ± 1.9%, respectively (Figure 2 B).  
SCFAs are interconverted by gut microbiota 
The individual 13C-SCFAs were administered on separate days to allow evaluating the extent 
of interconversion between the three SCFAs. After administration of 13C-acetate, the extent of 
its conversion into 13C-propionate and 13C-butyrate was determined by quantifying the 
appearance of 13C-propionate and 13C-butyrate in plasma. Interconversion was quantified in 
similar ways after administration of 13C-propionate and 13C-butyrate. The incorporation of 
13C-acetate into butyrate (Figure 3 A) was quantitatively the most significant interconversion 
but all interconversions were detected. To confirm that conversion of acetate into butyrate was 
due to bacterial and not to human metabolism, uncoated 13C-acetate capsules were 
administered. As these released 13C-acetate already in the proximal gastrointestinal tract, 
13C-acetate was absorbed before it had been in contact with bacteria and appeared in plasma 
14 
 
already after 120 min. No 13C-butyrate in plasma was observed, confirming that contact with 
bacteria is essential for the interconversion to occur (Figure 3 B and 3 C). 
Quantification of the butyrate-producing capacity of the intestinal microbiota 
To relate the interconversion of acetate into butyrate to the intestinal microbiota composition 
of the subjects, the butyrate-producing capacity in a faecal sample was quantified. RT-PCR 
was used to quantify genes coding for butyrate kinase and butyryl-CoA:acetate 
CoA-transferase which are the dominant terminal enzymes in the production of butyrate (Louis 
& Flint, 2007; Vital et al., 2013). In addition, the most abundant clusters of butyrate producing 
bacteria, i.e. Clostridium clusters IV and XIVa, were quantified (Figure 4 A). However, the 
extent of acetate into butyrate conversion was not significantly related to any of these 
parameters of butyrate-producing capacity (Figure 4 B-E).  
Utilization of colonic-derived propionate in gluconeogenesis 
Plasma 13C-glucose concentrations increased simultaneously with 13C-propionate 
concentrations (Figure 5 A). The cumulative amount of 13C-glucose was 23 ± 20.5 µmol.h.L-1. 
We calculated that 5.9 ± 4.7% of the colonic administered propionate was used for 
gluconeogenesis (Figure 5 B). 
Incorporation of acetate into fatty acids  
The 13C-enrichment and total concentrations of the most abundant plasma fatty acids, palmitic 
acid (C16:0), stearic acid (C18:0) and oleic acid (C18:1, n-9) were quantified after 13C-acetate 
administration. Enrichment was mainly observed in palmitic acid and to a lesser extent in 
stearic and oleic acid (Figure 5 C). Up to 12.0 ± 8.7%, 1.0 ± 0.9% and 1.0 ± 1.0% of 
administered acetate was assimilated into palmitic, stearic and oleic acid, respectively (Figure 
5 D). 
Incorporation of colonic-derived acetate and propionate into cholesterol 
After administration of 13C-acetate, 13C-cholesterol readily appeared in plasma whereas 
13C-cholesterol was hardly detectable after administration of 13C-propionate (Figure 5 E). Only 
0.101 ± 0.076% and 0.007 ± 0.005% of administered 13C-acetate and 13C-propionate were 
assimilated into cholesterol, respectively (Figure 5 F). 
Conversion of short-chain fatty acids into carbon dioxide 
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The extent to which 13C-substrates are converted to 13CO2 at the whole-body level is most often 
estimated from the excretion of 13CO2 in breath. After 12 h, the cumulative percentage of 
13C-label recovered as 13CO2 in breath after administration of 
13C-propionate amounted to 
47 ± 13%, whereas 33 ± 10% of administered 13C-acetate and 18 ± 3% of administered 13C-
butyrate was recovered (Figure 6). Application of the correction factor for the 13CO2 that is 
retained in the body indicated that up to 86 ± 24% of administered 13C-propionate, 60 ± 18% 
of administered 13C-acetate, and only 33 ± 6% of administered 13C-butyrate was oxidized into 
13CO2 within 12 h.  
Urinary excretion 
Subjects collected urine for 24 h in different fractions (0-4 h, 4-8 h, 8-12 h, 12-24 h) to allow 
quantification of the urinary excretion of 13C-SCFAs. After 24 h, only up to 0.031 ± 0.020% of 
13C-acetate, 0.008 ± 0.002% of 13C-propionate and 0.0006 ± 0.0003% of 13C-butyrate were 
retrieved in urine. 
 
Discussion 
By applying a direct, stable isotope based approach, the present study enabled to provide 
quantitative information on the uptake and elimination of SCFAs in different body 
compartments and their assimilation into biologically relevant molecules in humans. This 
information may contribute to deciphering the mechanistic link between fibre consumption and 
its health benefits.  
Colonic delivery of SCFA 
Targeting of orally administered compounds to the colon can be achieved using various 
strategies including the use of coatings with a pH-sensitive polymer, formulation of time-
released systems, use of carriers that are specifically degraded by colonic bacteria, covalent 
linkage of the compound with a carrier, bioadhesive systems and osmotic controlled drug 
delivery systems (for a review, see Charousia et al., 2003). These formulations have been 
mainly developed to target drugs to the colon either for treatment of local diseases such as 
Crohn’s disease or ulcerative colitis but also because of the potential to deliver therapeutic 
peptides or proteins. Due to absence of peptidases in the colon, peptide drug might be absorbed 
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unchanged after peroral administration. Targeted delivery of SCFA to the colon has previously 
been achieved using carriers such as starch (Annison et al. 2003) or inulin (Chambers et al., 
2014). Upon arrival in the colon, the carriers are fermented by the resident bacteria and release 
the SCFA that are attached to them. We preferred to use gelatine capsules with a pH-dependent 
coating as a convenient vehicle to deliver well known amounts of SCFA to the colon. 
Systemic availability of SCFAs 
Estimates of the extraction of the SCFAs during passage through the splanchnic bed have been 
reported and are based either on differences in SCFA concentrations in peripheral blood 
compared to their concentrations in portal blood obtained during abdominal surgery (Peters et 
al., 1992; Bloemen et al., 2009) or on isotope dilution experiments (Pouteau et al., 1996). 
Estimates for splanchnic extraction of acetate vary from 40-75% (Pouteau et al., 1996; Vogt et 
al., 2004) whereas an extraction value of 90% for propionate has been mentioned (Vogt et al., 
2004). As butyrate is the preferred energy source for colonocytes, the majority of absorbed 
butyrate may already be consumed by the colonic mucosa. According to Cook and Sellin 
(1998), 70-90% of butyrate is metabolized in the colonocytes (Cook & Sellin, 1998). Bloemen 
et al. showed that the release of butyrate from the liver is not significantly different from zero, 
suggesting a splanchnic extraction of almost 100% (Bloemen et al., 2009). Of note, all studies 
mention a wide interindividual variation in SCFA levels, both in peripheral and in portal blood 
(Peters et al., 1992; Bloemen et al., 2009). 
We combined colonic administration of 13C-labelled SCFA with intravenous administration 
of 2H-labelled SCFA to determine the SCFA systemic availability, assuming a similar 
behaviour of both types of labelled SCFA. Although simultaneous infusion of 13C-acetate and 
2H-acetate in the gut of pigs resulted in higher 13C-acetate than 2H-acetate enrichment in 
plasma, suggesting in vivo isotope exchange of the deuterium hydrogen atoms in acetate and 
thus underestimation of the deuterium enrichment (Kien et al., 1996), we did not find evidence 
for such isotope exchange in our study. Indeed, the ion masses used to quantify acetate and 
2H3-acetate were m/z 60 and 63, respectively, with no quantifiable ions at mass m/z 61 nor 62. 
Similarly, we did not find evidence for isotope exchange of 2H7-butyrate which was quantified 
using a fragment ion with m/z of 63, rather than the parent ion. Therefore, even if isotope 
exchange occurred in the remaining part of the molecule, which we can not exclude, this will 
not have affected our results. 2H5-propionate was quantified using the parent ion at m/z 79. 
Although smaller peaks at m/z 78 and 77 were visible suggesting isotope exchange, the same 
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ratio’s were observed in the infusion solution as in the plasma samples indicating that the 
exchange likely occurred in the ion source of the mass spectrometer rather than in vivo. 
The values for systemic availability of acetate (36%) and propionate (9%) obtained in this study 
correspond to a splanchnic extraction of 64% and 91%, respectively, which is in nice agreement 
with reported values. Also in the present study, a large interindividual variation was observed. 
In addition, the direct stable isotope approach enabled detecting 13C-butyrate in plasma after 
colonic administration of 13C-butyrate and to quantify its systemic availability (2%) or 
splanchnic extraction (98%).  
Metabolism of SCFAs 
Within 12 h after colonic administration, the vast majority of propionate (86%) was converted 
into CO2 of which 47% was recovered in breath. The remainder was retained in the body 
bicarbonate pool. Except from being a substrate for gluconeogenesis, no other pathways for 
incorporation of propionate into other metabolites are known and the fate of propionate seems 
to be a rapid and almost complete conversion into CO2, which proceeds most likely in the liver. 
These results do not allow differentiating between the fraction of propionate that is directly 
converted into CO2 and that used for gluconeogenesis followed by oxidation of the resulting 
glucose into CO2. After administration of 
13C-acetate, recovery in breath was lower compared 
to that of 13C-propionate. This may be explained by labelled C that does not appear as 13CO2 
but is exchanged in other metabolites. These are most likely metabolites of the tricarboxylic 
acid (TCA) cycle (van Hall, 1999), as acetate enters the TCA cycle after conversion into 
acetyl-CoA. This exchange is only temporary since the resulting metabolites re-enter the 
oxidative pathways at a later time. This also explains the observation that breath 13CO2 
recoveries after intravenous 13C-acetate infusion increase with the duration of the infusion and 
only reach a plateau after 12 h of infusion (Mittendorfer et al., 1998). Breath 13CO2 recoveries 
after colonic administration of 13C-acetate have not been reported in literature. Reported 13CO2 
recoveries after intravenous 13C-acetate administration vary from 40% to 81% (Wolfe & 
Jahoor, 1990; Pouteau et al., 1996; Mittendorfer et al., 1998). 
The low recovery of 13CO2 after administration of 
13C-butyrate (33%) is probably in part due 
to exchange of the label into TCA metabolites. After absorption in the colonocytes, butyrate is 
taken up in the mitochondria of the cells where it undergoes the β-oxidation pathway, which 
involves a series of five enzymes, to form acetyl-CoA that subsequently enters the TCA cycle 
(De Preter et al., 2012). A few other studies that compared the rate of colonic butyrate oxidation 
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in patients with ulcerative colitis and healthy controls, report on 13/14CO2 recoveries in breath 
after colonic administration of 13C- or 14C-labelled butyrate. Six hours after rectal instillation 
of 14C-butyrate enemas, 52.9 (44.4-61.5)% of administered label was retrieved in breath (Den 
Hond et al., 1998). In another study, about one fourth of rectally instilled 13C-butyrate was 
recovered as 13CO2 after 4 hours (Simpson et al., 2000). After intravenous infusion of 
13C-butyrate in five healthy subjects, the 6-h cumulative excretion of 13CO2 amounted to 
49.9 ± 2.2% (Den Hond et al., 1998). For all 13C-SCFA, higher fractions of administered dose 
are excreted in breath as 13CO2 than appearing in plasma indicating that they are metabolized 
prior to arrival in the systemic circulation, i.e. presumably in the colonocytes and liver. 
In the human kidney, monocarboxylate transporters (MCTs) are responsible for the 
reabsorption of SCFAs and ketone bodies (Halestrap & Meredith, 2004). Although lactate is 
quantitatively the most important substrate for these transporters, they have been shown to also 
reabsorb SCFAs. As a consequence, urinary excretion of SCFAs is low. After continuous 
infusion of sodium butyrate for 10 days in patients with acute leukaemia, only 0.21 ± 0.04‰ 
of the administered dose was retrieved in urine (Miller et al., 1987). In healthy subjects, urinary 
levels of SCFA have been reported in a range of 0.8-130 µM for acetate and below 3 µM for 
propionate and butyrate (Perry et al., 1970).  
In vivo cross-feeding 
Cross-feeding involves the supply of breakdown products of carbohydrates after partial 
hydrolysis by primary degraders as secondary substrates to other bacteria (De Vuyst & Leroy, 
2011). In particular, acetate is known to function as an intermediate in cross-feeding 
interactions between colon bacteria, and plays a key role in colonic butyrate production 
(Morrison et al., 2006; Riviere et al., 2015). Morrison et al. incubated human faecal slurries in 
vitro with 2H-labelled SCFAs and quantified the interconversion between the SCFAs 
(Morrison et al., 2006). After 6 h, 0.28 mol/mol labelled acetate was incorporated into butyrate. 
In the present study, conversion of 13C-acetate into 13C-butyrate was estimated to be about 
24%. Although the contact time of 13C-acetate with the intestinal microbiota was shorter in 
vivo than in vitro as 13C-acetate was rapidly absorbed into the plasma after release from the 
CDCs, the value is only slightly lower than the Morrison data, suggesting that this 
interconversion proceeds quite rapidly. Whereas no evidence for incorporation of 2H-acetate 
into propionate or 2H-propionate into butyrate was found in the in vitro study, all possible 
interconversions could be detected, albeit to a lower extent than the acetate-into-butyrate 
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interconversion. This discrepancy is likely due to the different analytical techniques used in 
both studies. Morrison et al. applied GC-MS analysis which allowed differentiating between 
different isotopomers of the SCFAs, but is a less sensitive technique than the isotope ratio mass 
spectrometry applied in the present study. In a recent study in mice, enrichments of cecal 
SCFAs were quantified after a 6-h cecal infusion of 13C-labelled SCFA. A high conversion was 
observed from acetate into butyrate, a low conversion from butyrate into acetate and between 
butyrate and propionate and very little interconversion between acetate and propionate (den 
Besten et al., 2013a). 
Propionate as a substrate for gluconeogenesis 
Studies in lactating cows report that up to 61% of glucose in blood is derived from 
gluconeogenesis with propionate as the substrate (Wiltrout & Satter, 1972). In sheep, 
corresponding values between 42% and 59% have been reported (Leng et al., 1967). On the 
other hand, up to 32% of colonic-derived propionate is incorporated into glucose in sheep and 
up to 62% in mice (Leng et al., 1967; den Besten et al., 2013a). Compared to those values, the 
extent of incorporation of colonic-derived propionate into glucose (5.9%) is limited in humans, 
as shown by the present study. Indeed, propionate is the major substrate for gluconeogenesis 
in ruminants (Bergman, 1990) whereas in humans, lactate and pyruvate are the major 
gluconeogenic substrates with minor contributions of alanine and glycerol (Garber et al., 1974). 
Several methods based on stable isotope technology have quantified in vivo the contribution of 
gluconeogenesis to the glucose production in humans (Previs & Brunengraber, 1998). 
However, contributions of all gluconeogenic substrates are included in these estimates and no 
human data on the contribution of propionate to gluconeogenesis are available.  
More recently, it has been shown in rats that propionate is incorporated into glucose at the level 
of the intestine (De Vadder et al., 2014). The resulting glucose is sensed in the walls of the 
portal vein and induces a nervous signal to the brain that influences food intake and glucose 
homeostasis. These results may provide a mechanistic role for propionate in the beneficial 
effects of dietary fibre. Unfortunately, due to inability to obtain portal blood from healthy 
subjects, our results do not allow determining whether the observed incorporation of 
13C-propionate into glucose occurs in the intestine or in the liver.  
Incorporation of acetate into fatty acids 
Indirect methods to estimate de novo lipogenesis such as indirect whole-body calorimetry as 
well as direct methods such as 2H2O infusion and mass isotopomer distribution analysis 
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(MIDA) confirmed that de novo lipogenesis (DNL) is a quantitatively minor pathway under 
normal conditions of typical high-fat diets (Hellerstein et al., 1991; Hellerstein et al., 1996; 
Bjorntorp and Sjostrom, 1978). Absolute DNL was estimated at less than 1 g synthesized per 
day which is low compared to a dietary fat intake of typically 100 g per day (Hellerstein et al., 
1996). Studies using MIDA intravenously infuse 13C-acetate to enrich the acetyl-CoA-
precursor pool and express the fractional hepatic DNL as fraction of newly synthesised lipid 
compared to the lipid already present and not as fraction of administered acetate incorporated 
in the lipid. As a consequence, it is not possible to compare the results obtained in the present 
study to those results reported in literature. Almost 15% of colonic-administered acetate was 
incorporated into fatty acids in the present study. However, this only corresponds to an absolute 
amount of 0.229 ± 0.175 g of newly synthesized fatty acids which is still far below the 1 g 
threshold. It needs to be taken into account that only 5 mmol of 13C-labelled acetate was 
administered in the colon delivery capsules whereas the amount of acetate produced in the 
colon on a western diet (20 g of dietary fibre) has been estimated at about 150 mmol per day 
(Wolever et al., 1995). 
Incorporation of acetate and propionate into cholesterol 
It has been calculated that the rate of de novo synthesis of cholesterol amounts to 
10 ± 6 mg.kg-1.day-1 in healthy adults (Renfurm et al., 2004). As the biosynthesis of cholesterol 
starts from the two-carbon acetate group of acetyl-CoA, it has been suggested that dietary fibres 
that are fermented into a high proportion of acetate might increase serum cholesterol levels. 
However, unlike propionate and butyrate, the majority of plasma acetate originates from 
endogenous metabolism and the contribution of colonic-derived acetate to cholesterol synthesis 
may well be less important. Indeed, the present study showed that less than 0.1% of colonic-
administered acetate was incorporated into cholesterol. This value is of the same order of 
magnitude as the value of 0.7% reported by Hellman et al. after oral administration of 
14C-acetate (Hellman et al., 1954). In mice, the fractional synthesis of cholesterol from acetate 
was 0.7 ± 0.1% (den Besten et al., 2013a). Propionate did not contribute to cholesterol 
synthesis neither in this study nor in the study in mice mentioned before (den Besten et al., 
2013a). 
Limitations of the present study 
For the calculation of the systemic availability, it was assumed that the absorption of the 
13C-SCFAs from the colonic lumen was quantitative. The major part of SCFA is transported in 
21 
 
dissociated form across the apical membrane of the colonocytes by the monocarboxylate 
transporter 1 (MCT-1), the electrogenic sodium dependent monocarboxylate transporter 1 
(SMCT-1) or an SCFA-HCO3
- exchanger of unknown identity (den Besten et al., 2013).  It is 
indeed generally believed that the colon has a large capacity to absorb SCFAs with estimates 
of 6.1-12.6 µmol/cm².h (He et al., 2006). As the human colon has a mucosal surface area of 
about 20000 cm² (Helander & Fandriks, 2014), up to 120-250 mmol of SCFAs could be 
absorbed per hour. To confirm a quantitative SCFA absorption, a complete stool collection for 
3-5 days after each test day would have been required for quantifying residual 13C-SCFAs. This 
would have placed an additional burden on the protocol which was already onerous for the 
participants and was therefore not performed. Only one stool sample was collected for the 
analysis of the microbial butyrate-producing capacity. 
In this study, the metabolic fate of the SCFA was evaluated in standardized feeding conditions 
(i.e. after administration of a non-fermentable standard breakfast and lunch). Whether the 
oxidation and/or incorporation of SCFA in biomolecules differs in fasting conditions remains 
to be investigated. 
 
Conclusions 
The setup and methodology used in the present study allowed quantifying the percentages of 
acetate, propionate and butyrate originating from the colon that reached the systemic 
circulation. In addition, the metabolism and assimilation of acetate, propionate and butyrate 
into biologically relevant molecules were measured.  
In the future, these results will allow evaluating and quantifying SCFA production of varying 
13C-labelled fibres in the human colon by measuring 13C-labelled SCFA concentrations in 
blood and multiplying the amounts of SCFAs that reached the plasma with the systemic 
availability index calculated in this study. In addition, the availability of plasma clearance 
values for each SCFA will allow calculating fluxes under different conditions when combined 
with plasma SCFA measurements. 
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Figures 
 
 
Figure 1: In vitro and in vivo evaluation of the performance of the colon delivery capsules. (A) 
In vitro dissolution profile of colon delivery capsules at different pH, n = 2. (B) A 
representative example of the appearance of 14CO2 and 
13CO2 in breath after administration of 
13C-acetate colon delivery capsules. The simultaneous rise in breath of 14CO2 and 
13CO2 
indicates a correct delivery of 13C-acetate in the colon. (C) Comparison of the time of release 
of the 13C-SCFAs from the capsules (indicated by the time point at which 20 % of the 
cumulative amount recovered was obtained, t20%) and arrival of the test meal in the colon 
(indicated by the orocecal transit time, OCTT), n = 36 except for OCTT n = 30. Results are 
expressed as means and standard deviations. 
  
0 50 100 150 200
0
50
100
150 pH 6,3
pH 6,8
pH 7,0
pH 7,2
time (min)
%
 r
e
le
a
s
e
0 200 400 600
0
20
40
60
80
100
0
50
100
150
200
13CO2
14CO2
time (min)
D
e
lta
 o
v
e
r 
b
a
s
e
lin
e
n
e
tto
 d
e
s
in
te
g
ra
tio
n
 p
e
r m
in
u
te
t20% OCTT
0
200
400
600
800
tim
e
 (
m
in
)
A
C
B
28 
 
 
Figure 2: Calculation of the systemic availability of colonic-administered 13C-SCFAs. Typical 
graph depicting (A) 13C-acetate concentrations in plasma versus time. (B) Systemic availability 
results of acetate, propionate and butyrate for all 12 subjects. Results are expressed as means 
and standard deviations. 
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Figure 3: Cross-feeding of SCFAs. (A) Overview and quantitative indication of the 
interconversions between acetate, propionate and butyrate, n = 12. (B) Appearance of 13C-
acetate in plasma after administration of a coated and uncoated capsule filled with 13C-acetate. 
Without coating, 13C-acetate was released in the proximal intestine and appears at an earlier 
time in plasma compared to a coated capsule. (C) Appearance of 13C-butyrate in plasma after 
administration of a coated and uncoated capsule filled with 13C-acetate. 13C-butyrate is only 
formed when 13C-acetate is properly released in the colon. 
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Figure 4: Butyrate-producing capacity. (A) Gene copy numbers of butyrate-producing colon 
bacteria and butyrate-producing colon enzymes in faecal samples, n = 11. (B-C) Correlation 
between acetate-into-butyrate conversion and enzymes involved in butyrate synthesis, n = 11. 
(D-E) Correlation between acetate-into-butyrate conversion and the most abundant butyrate-
producing bacteria, n = 11. 
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Figure 5: Assimilation of 13C-SCFAs in biologically relevant molecules. (A) Typical example 
that shows the appearance of 13C-propionate followed by 13C-glucose in plasma after colonic 
administration of 13C-propionate. (B) Fraction of administered 13C-propionate recovered in 
glucose, n = 12. (C) Typical example that shows the appearance of 13C-acetate followed by 
13C-palmitate, 13C-stearate and 13C-oleate in plasma after colonic administration of 13C-acetate. 
(D) Fraction of administered 13C-acetate recovered in palmitate (C16), stearate (C18) and 
oleate (C18:1), n = 12. (E) Typical examples that show the appearance of 13C-acetate and 
13C-propionate followed by 13C-cholesterol in plasma after colonic administration of 
13C-acetate. (F) Fraction of administered 13C-acetate and 13C-propionate recovered in 
cholesterol, n = 12. Results are expressed as means and standard deviations. 
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Figure 6: Recovery of 13C-acetate, 13C-propionate and 13C-butyrate in breath as 13CO2. Results 
are expressed as means and standard deviations, n = 12. 
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